Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants

Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral drug that has been shown to reduce the risk of hospitalization, severe COVID-19 and mortality among mild-to-moderate COVID-19 patients who are at risk of developing severe disease This article is protected by copyright. All rights reserved.